Please login to the form below

Not currently logged in
Email:
Password:

EC approves S-A/ BMS dual antiplatelet drug

Sanofi-aventis and Bristol-Myers Squibb have received EC approval for their dual antiplatelet combination tablet DuoPlavin/DuoCover

Sanofi-aventis (S-A) and Bristol-Myers Squibb (BMS) have received European approval for their dual antiplatelet combination tablet DuoPlavin/DuoCover (clopidogrel 75mg and acetylsalicylic acid 100mg or 75 mg) by the European Commission (EC).

DuoPlavin/DuoCover is a fixed dose combination medicine for the prevention of atherothrombotic events in adult patients already taking both clopidogrel (Plavix) and acetylsalicylic acid (ASA). 

The combination treatment is intended for continuation of therapy in non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention and for the treatment of ST-segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.

Plavix (also produced by S-A and BMS) is recommended for daily use by patients who have had a recent heart attack or stroke, or have poor circulation in the legs that may cause pain during exercise, such as walking, and may be relieved by rest (known as peripheral artery disease, or PAD). 

Plavix is also recommended in addition to ASA for patients who have been hospitalised with heart-related chest pain (unstable angina) or have had a heart attack.

The new dual formulation has the added benefit of being a single tablet and therefore helps to reduce patients' daily pill burdens.

25th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics